Lipsosomal Amphotericin B for Treatment of Cutaneous Leishmaniasis
| Autor: | Roseanne A. Ressner, Alan J. Magill, Josh Hartzell, Glenn Wortmann, Michael Zapor, Joseph Pierson, Amy C. Weintrob, Susan Fraser |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Antibiotics Antiprotozoal Agents Leishmaniasis Cutaneous Young Adult Pharmacotherapy Cutaneous leishmaniasis Amphotericin B Virology medicine Humans Dosing Adverse effect Retrospective Studies business.industry Leishmaniasis Articles Middle Aged medicine.disease Dermatology Surgery Regimen Treatment Outcome Infectious Diseases Liposomes Female Parasitology business medicine.drug |
| Zdroj: | The American Journal of Tropical Medicine and Hygiene. 83:1028-1033 |
| ISSN: | 1476-1645 0002-9637 |
| Popis: | Treatment options for cutaneous leishmaniasis in the United States are problematic because the available products are either investigational, toxic, and/or of questionable effectiveness. A retrospective review of patients receiving liposomal amphotericin B through the Walter Reed Army Medical Center for the treatment of cutaneous leishmaniasis during 2007-2009 was conducted. Twenty patients who acquired disease in five countries and with five different strains of Leishmania were treated, of whom 19 received a full course of treatment. Sixteen (84%) of 19 experienced a cure with the initial treatment regimen. Three patients did not fully heal after an initial treatment course, but were cured with additional dosing. Acute infusion-related reactions occurred in 25% and mild renal toxicity occurred in 45% of patients. Although the optimum dosing regimen is undefined and the cost and toxicity may limit widespread use, liposomal amphotericin B is a viable treatment alternative for cutaneous leishmaniasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|